Phase 1, FIH, Open-label, Nonrandomized, Multicenter Study of JZP815 in Participants With Advanced or Metastatic Solid Tumors Harboring Alterations in the MAPK Pathway
This study is testing a new experimental drug called JZP815 to see if it can safely shrink or stop the growth of solid tumors. It is designed for patients whose cancer has specific genetic changes in a signaling process called the MAPK pathway, which helps control how cells grow.
You may be eligible if you are 18 or older and have an advanced solid tumor that has not responded well to standard treatments. Your medical team will also check that you are generally active and do not have other serious health issues like heart problems or active infections.
As this is an early-phase study, the primary focus is to find the best dose of the new drug and monitor how your body reacts to it. You will undergo regular medical check-ups and imaging scans to track how your tumor responds to the treatment.
The study is currently recruiting patients at medical centers in Los Angeles, California; Denver, Colorado; and Orlando, Florida. You should speak with your doctor to see if one of these locations is a good fit for you.
- 1The study evaluates a new medication for cancers that have stopped responding to standard care.
- 2Participation requires a confirmed genetic change in your tumor known as a MAPK pathway alteration.
- 3This is a Phase 1 study, meaning the main goal is to ensure the treatment is safe and to determine the right dosing.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.